[ad_1]
An extraordinary meeting of the EMA’s Committee for Medicinal Products for Human Use (CHMP) is scheduled for December 21, the authority announced. The meeting originally scheduled for December 29 will be held if necessary. The CHMP recommendations must be approved by the EU Commission, but this is considered safe for the vaccine.
Initially, the media reported on an earlier schedule. BioNTech declined to comment on this. The vaccine developer confirmed that together with its partner Pfizer, up to 50 million doses of vaccines would be available by the end of the year. You are in progress.
The EMA has come under increasing pressure from EU governments to accelerate approval of the crown vaccine from BioNTech and Pfizer. The pressure has mounted since emergency approvals in Britain and the United States, Reuters learned Monday from various insiders. BioNTech and Pfizer had submitted an application to the EMA two weeks ago for conditional marketing authorization for their Covid-19 vaccine.
Meanwhile, the US FDA has classified the Corona vaccine from the Modern pharmaceutical company as safe and effective. In an analysis released Tuesday, the agency certifies that the candidate vaccine has a “positive safety profile.” Data from around 30,350 clinical trial participants have shown that “there are no particular safety concerns” that would prevent emergency approval.
The vaccine is also “highly effective” in preventing an outbreak of the Covid-19 lung disease caused by the coronavirus, the FDA writes. The pharmaceutical authority confirms an effectiveness of 94.1 percent.
[ad_2]
